Dennis S Yamashita

US Patent:

6518267, Feb 11, 2003

Filed:

Nov 21, 2000

Appl. No.:

09/700828

Inventors:

William Edward Bondinell - Wayne PA
Renee Louise DesJarlais - St. Davids PA
Daniel Frank Veber - Ambler PA
Dennis Shinji Yamashita - King of Prussia PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31535

US Classification:

5142315, 5142352, 514332, 514336, 514312, 514340, 514357, 514464, 544106, 544111, 544129, 546156, 546186, 546192, 546193, 546195, 546207, 549469

Abstract:

The present invention provides bis-aminomethyl carbonyl protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Pagets disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

US Patent:

6562842, May 13, 2003

Filed:

May 30, 2002

Appl. No.:

10/160314

Inventors:

Dennis Shinji Yamashita - King of Prussia PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31443

US Classification:

514337, 514312, 514347, 514407, 514445, 514468, 514522, 514533, 514529, 5483701, 5462841, 546293, 546153, 549 65, 549461, 558389, 560 13, 560158

Abstract:

The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Pagets disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

US Patent:

6586466, Jul 1, 2003

Filed:

Apr 20, 2001

Appl. No.:

09/839410

Inventors:

Dennis Shinji Yamashita - King of Prussia PA

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61K 31165

US Classification:

514483, 514332, 514357, 546265, 546335, 560158

Abstract:

The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Pagets disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

US Patent:

7071184, Jul 4, 2006

Filed:

Mar 7, 2001

Appl. No.:

10/239343

Inventors:

Maxwell D. Cummings - Strafford PA, US
Daniel F. Veber - Ambler PA, US
Dennis S. Yamashita - Wayne PA, US

Assignee:

SmithKline Beecham Corporation - Philadelphia PA

International Classification:

A61P 19/00
A61K 31/55
C07D 403/00
C07D 405/00
C07D 409/00

US Classification:

51421704, 51421103, 51421703, 51421705, 51421706, 51421707, 51421708, 51421709, 5142171, 51421711, 540525, 540596, 540597, 540598, 540599, 540601, 540602, 540603, 540604

Abstract:

The present invention provides Calkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.

US Patent:

7109233, Sep 19, 2006

Filed:

May 21, 2003

Appl. No.:

10/515118

Inventors:

Jae U. Jeong - Collegeville PA, US
Dennis S. Yamashita - Collegeville PA, US

Assignee:

SMithKline Beecham Corporation - Philadelphia PA

International Classification:

C07D 267/02
C07D 513/00
C07D 515/00
A61K 31/38

US Classification:

514430, 540488, 540492, 540484, 540485, 540490, 514431

Abstract:

This invention relates in general to certain substituted substituted 1,1,4-1l-trioxo[1,2]thiazepan-4-ylamides of formula I.

US Patent:

7405209, Jul 29, 2008

Filed:

Jun 14, 2005

Appl. No.:

11/152745

Inventors:

Yu Ru - Wayne PA, US
Daniel Frank Veber - Ambler PA, US
Maxwell David Cummings - Strafford PA, US
Scott Kevin Thompson - Phoenixville PA, US
Dennis Shinji Yamashita - Wayne PA, US

Assignee:

SmithKline Beecham Corporation - Philadelphia PA
SmithKline Beecham p.l.c. - Brentford, Middlesex

International Classification:

A61P 19/00
A61K 31/55
A61K 31/00
C07D 223/08
C07D 403/00
C07D 405/00
C07D 409/00

US Classification:

51421103, 51421703, 51421704, 51421705, 51421706, 51421707, 51421708, 51421709, 5142171, 51421711, 540525, 540596, 540597, 540598, 540599, 540601, 540602, 540603, 540604

Abstract:

The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

US Patent:

7491728, Feb 17, 2009

Filed:

Apr 7, 2004

Appl. No.:

10/552363

Inventors:

Irina V. Shcherbakova - Salt Lake City UT, US
Guangfei Huang - Alchua FL, US
Otto Geoffroy - Alchua FL, US
John Fox - Salt Lake City UT, US
Robert Marquis - King of Prussia PA, US
Dennis Shinji Yamashita - King of Prussia PA, US
Juan Luengo - King of Prussia PA, US
Wenyong Wang - King of Prussia PA, US

Assignee:

SmithKline Beecham Corp. - Philadelphia PA

International Classification:

A61K 31/517
A61K 31/50
C07D 403/14
C07D 239/30
C07D 239/46
A61P 35/00

US Classification:

51426621, 514269, 5142581, 51426631, 544284, 544289, 544298, 544253

Abstract:

The pyrimidinone compounds are disclosed. Methods of preparing the pyrimidinone compounds are also disclosed.

US Patent:

7563784, Jul 21, 2009

Filed:

Apr 25, 2006

Appl. No.:

11/410558

Inventors:

Maxwell D. Cummings - Strafford PA, US
Yu Ru - Wayne PA, US
Scott K. Thompson - Phoenixville PA, US
Daniel F. Veber - Ambler PA, US
Dennis S. Yamashita - Wayne PA, US

Assignee:

SmithKline Beecham Corporation - King of Prussia PA

International Classification:

A61P 19/08
A61P 19/10
A61K 31/55
C07D 401/00
C07D 403/00
C07D 413/00

US Classification:

51421103, 51421703, 51421704, 51421705, 51421706, 51421707, 51421708, 51421709, 5142171, 51421711, 540525, 540596, 540597, 540598, 540599, 540601, 540602, 540603, 540604, 540605

Abstract:

The present invention provides Calkyl-4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease; and parasitic diseases, including malaria, by administering to a patient in need thereof one or more compounds of the present invention.